Efficacy and safety of Tenofovir disoproxil fumarate (TDF) or Entecavir (ETV) combined with interferon for the treatment of chronic hepatitis B: a systematic review and meta-analysis

Authors:

Open Access

27 July 2026

journal article
review article
Published by Springer Nature in Virology Journal

Abstract

Whether tenofovir disoproxil fumarate (TDF) or entecavir (ETV) combined with pegylated interferon offers superior functional cure potential in chronic hepa

Keywords

Funding Information

National Natural Science Foundation of China (82570707)
Major Science and Technology Innovation Project of Fujian Province (2023Y9269)
Natural Science Foundation of Fujian Province (2023J01239)

This publication has 22 references indexed in Scilit:

Pegylated interferon‐α‐2b combined with tenofovir disoproxil fumarate, granulocyte‐macrophage colony‐stimulating factor, and hepatitis B vaccine treatment for naïve HBeAg‐positive chronic hepatitis B patients: A prospective, multicenter, randomized controlled study
Journal of Medical Virology, 2022
Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B
Hepatology International, 2021
Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience
Clinical Therapeutics, 2021
A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study
Journal of Infection and Chemotherapy, 2020
Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-naïve chronic hepatitis B patients: a prospective and randomized controlled trial
Chinese Medical Journal, 2020
PD-L1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug Entecavir
International Immunology, 2020
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
Digestive Diseases and Sciences, 2018
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Gastroenterology, 2016
Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)
Hepatology, 2014
A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B
Clinical Infectious Diseases, 2014